$PATH

UiPath (NYSE: PATH) CEO sells 1.4M shares, still holds 26,491,238

UiPath (PATH) CEO Daniel Dines sold 1.4M shares at $16.07 each under a Rule 10b5-1 plan, retaining 26.5M shares. The sale occurred on 2026-08-19 and totaled $22.54M.

Original reporting
Published Aug 20, 2026, 12:41 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 1:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$PATH
Neutral
medium confidence
Mentioned
$PATH
Relevance
6/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$PATHNeutralLow
01

Why it matters

Insider sell of $22.5M may cause short‑term price dip but likely limited impact.

02

Market read

Primary insider sale; modest trading relevance for PATH.

03

What to watch

Potential upcoming financing or strategic moves not disclosed.

Relevance 6/10Novelty 6/10Timing: after‑hours 2026‑08‑19

Background

Form 4 filing discloses insider transaction under a pre‑arranged selling plan.

Company-level read

Ticker impact

$PATHNeutralMedium confidence
Context

CEO Daniel Dines sold 1,402,347 PATH shares on 2026-08-19 under a Rule 10b5‑1 plan.

Expected impact

Potential modest downward pressure in near‑term trading.

Evidence & confidence

Sale size ($22.5M) is material for a mid‑cap, but 10b5‑1 plans are pre‑scheduled and not necessarily indicative of new information.

Market effects

None significant; RPA sector unchanged.

No regional effect beyond UiPath shareholders.

Limited to investors tracking insider activity.

Counterpoint

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Daniel Dines

    CEO and Chairman of UiPath

Related articles

$PATHMedAI 8/10

Analysts Have a Wall of Holds on Figma, UiPath and GitLab but Institutions Are Quietly Loading Up

Analysts have issued 41 Holds across 61 ratings for UiPath, GitLab, and Figma, with consensus targets below current prices for two. Institutions hold 65% to 95% of the float, building positions despite cautious analyst sentiment. UiPath and GitLab have surged 58% and 36% in one month, respectively, exceeding analyst targets. Figma's target aligns with its current price. All three companies reported strong revenue growth in recent quarters.

$PLTRHighAI 9/10

Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally

Palantir Technologies reported Q2 2026 revenue of $1.94B, up 92.8% YoY, beating $1.81B consensus, and raised FY2026 revenue guidance to about $8.15B. U.S. commercial total contract value reached a record $2.1B. Shares rose about 16% to $145.50 after Deutsche Bank upgraded to Buy with a $200 target; C3.ai and UiPath did not rally.

$PLTRMed

JFrog, Zscaler, Palo Alto Networks, Shopify, and UiPath Shares Are Soaring, What You Need To Know

In Tuesday premarket trading, Palantir’s (PLTR) reported Q2 results and raised full-year revenue outlook drove a broad rally in enterprise software and cybersecurity peers. The article cites Palantir’s 26% jump and links the move to lower Treasury yields after geopolitical de-escalation. It also lists gains for JFrog (FROG), Zscaler (ZS), Palo Alto Networks (PANW), Shopify (SHOP), and UiPath (PATH).

$PATHMed

UiPath (NYSE:PATH) Shares Fall as Q2 Outlook Indicates Reduced ARR Growth

NEW YORK, July 30, 2026, 2:01 p.m. EDT — Shares of UiPath NYSE:PATH declined after the company forecasted slower additions to annualized recurring revenue for the second quarter. The stock dropped 3.3% to $12.18 in early U.S. trading. Initial estimates indicate Q2 guidance suggests net new ARR between $28 million and $33 million. Initial estimate: market value, adjusted for cash, is approximately 2.8 times the projected revenue for fiscal 2027. UiPath shares declined even as U.S.

$PATHMed

PATH Stock Slips As UBS Trims Price Target

UiPath (PATH) shares were up about 7.3% on AI automation optimism, but UBS cut its price target to $12 from $13 while keeping a Neutral rating. Street consensus remains Hold with a mean target near $13.47 versus a price around $10.81. The article also cites UiPath’s annual revenue of about $1.61B and recent quarterly net income of about $22.5M.

$PATHMed

UiPath shares rebound as Wall Street warms to its AI-agent pivot

UiPath shares rebounded about 15% over five days after the company reported its first-quarter GAAP operating profit of $28m and GAAP profit for the first time in a first quarter, following a loss a year earlier. Revenue rose 17% to $418m; annual recurring revenue reached $1.9bn (+12%). UiPath is pivoting to AI agents, including its WorkFusion acquisition.